One more week to apply! Come join us in Human Technopole if you are interested in B cell biology, CRISPR screens and immunogenomics.

Welcome MSD to the Open Targets consortium. Will be great to work together to improve target ID and prioritisation.

We welcome Julio Saez-Rodriguez Julio Saez-Rodriguez as our new Head of Research! Associate Director for EMBL-EBI Services Jo McEntyre Jo McEntyre has been promoted to Deputy Director of EMBL-EBI & Rolf Apweiler is stepping back to Associate Director as he looks towards retirement.

Join us for these exciting projects using Large Language Models and knowledge graphs, building on biocypher.org, within Open Targets led by Sebastian Lobentanzer 🕸

📢 On World #IBD Day weekend Carl Anderson and I are delighted to introduce Open-IBD! £11M funding from Open Targets and Wellcome Sanger Institute Open-IBD will study serial multi-omics and longterm outcomes from diagnosis in 1,000 people with IBD More👇 opentargets.org/news/open-ibd-…

Launching ahead of #WorldIBDDay, Open-IBD is an ambitious project that aims to uncover new ways to predict, monitor, and treat #Crohnsdisease and #ulcerativecolitis 🔎 Read more about it here 👇 sanger.ac.uk/news_item/ambi…

Designing projects we look for opportunities to make a difference in our understanding of disease and where we can work with exceptional scientists. Looking forward to what we can accomplish here for IBD with an amazing team.

On #WorldIBDDay, Open Targets project lead Carl Anderson introduces our most ambitious project yet: Open-IBD!

Very happy to share my post-doc work now online nature from ludovic vallier. Using snRNAseq, tissue clearing and organoids, we found plasticity occurs between cholangiocytes and hepatocytes in human chronic liver disease. nature.com/articles/s4158…

New paper from ludovic vallier is online. "Acquisition of epithelial plasticity in human chronic liver diseases". Amazing work from Chris Gribben and Vasileios Galanakis in collaboration with Irina Mohorianu and Mike Alison. Few key points: 1/ link.springer.com/article/10.103…

Congratulations to ludovic vallier for their latest work on liver regeneration, published in nature! 🎉 This Open Targets project showed that chronic injury creates an environment that induces cellular plasticity — potentially paving the way for regenerative therapies

🚨 Open Targets Platform 24.06 has been released!

Open Targets Platform summer 🌻 release is out with enhanced data and improved therapeutic hypothesis-building capabilities. We continue our sustained effort to connect the necessary dots and understand the risks/benefits of early drug discovery decision-making.

Happy to share the latest work led by Krista Freimann in my lab. We performed the largest trans-eQTL meta-analysis in a single cell type: 3,734 LCL samples from 9 individual studies. medrxiv.org/content/10.110…

Genetic evidence halves the odds of early clinical trial stoppage 🧬💊 Published today in Nature Genetics, Olesya Razuvayevskaya trained a machine learning classifier to analyse the free-text reasons explaining why 28,842 clinical trials stopped 3 key points: nature.com/articles/s4158…

Open Targets meets David Van Heel of Genes & Health! Genes&Health is a health research study of British-Bangladeshi and Pakistani-origin volunteers, ethnicities which are missing from many clinical trials and cohorts Thank you David for fascinating insights into this research!

Why do clinical trials stop? Researchers from Open Targets and EMBL-EBI have developed a machine learning model to analyse clinical trial data. They found a correlation to suggest that trials less supported by genetic evidence are more likely to fail. ebi.ac.uk/about/news/res…

Time flies when you’re having fun…

🚨 Open Targets Platform 24.09 is out today!